These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25128418)

  • 1. Involvement of glucagon-like peptide 1 in the glucose homeostasis regulation in obese and pituitary-dependent hyperadrenocorticism affected dogs.
    Miceli DD; Cabrera Blatter MF; Gallelli MF; Pignataro OP; Castillo VA
    Res Vet Sci; 2014 Oct; 97(2):211-7. PubMed ID: 25128418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism.
    Montgomery TM; Nelson RW; Feldman EC; Robertson K; Polonsky KS
    J Vet Intern Med; 1996; 10(3):116-22. PubMed ID: 8743209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased insulin sensitivity and glucose tolerance in spontaneous canine hyperadrenocorticism.
    Peterson ME; Altszuler N; Nichols CE
    Res Vet Sci; 1984 Mar; 36(2):177-82. PubMed ID: 6371957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of beta-cell sensitivity to glucose and first-phase insulin secretion in obese dogs.
    Verkest KR; Fleeman LM; Rand JS; Morton JM
    Am J Vet Res; 2011 Mar; 72(3):357-66. PubMed ID: 21355739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compensation for obesity-induced insulin resistance in dogs: assessment of the effects of leptin, adiponectin, and glucagon-like peptide-1 using path analysis.
    Verkest KR; Fleeman LM; Morton JM; Ishioka K; Rand JS
    Domest Anim Endocrinol; 2011 Jul; 41(1):24-34. PubMed ID: 21474268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose of insulin detemir controls glycaemia, insulinemia and prevents diabetes mellitus progression in the dog with pituitary-dependent hyperadrenocorticism.
    Miceli DD; Gallelli MF; Cabrera Blatter MF; Martiarena B; Brañas MM; Ortemberg LR; Gómez NV; Castillo VA
    Res Vet Sci; 2012 Aug; 93(1):114-20. PubMed ID: 21807392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic profiling of serum from dogs with pituitary-dependent hyperadrenocorticism.
    Muñoz-Prieto A; Rubić I; Horvatic A; Rafaj RB; Cerón JJ; Tvarijonaviciute A; Mrljak V
    Res Vet Sci; 2021 Sep; 138():161-166. PubMed ID: 34147706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.
    Teshima T; Matsumoto H; Okusa T; Uchiyama R; Koyama H
    PLoS One; 2016; 11(11):e0166267. PubMed ID: 27824928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preliminary evaluation of the circulating leptin/adiponectin ratio in dogs with pituitary-dependent hyperadrenocorticism and concurrent diabetes mellitus.
    Kim H; Kang JH; Jung DI; Kang BT; Chang D; Yang MP
    Domest Anim Endocrinol; 2021 Jan; 74():106506. PubMed ID: 32920447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral glucose leads to a differential response in glucose, insulin, and GLP-1 in lean versus obese cats.
    Hoenig M; Jordan ET; Ferguson DC; de Vries F
    Domest Anim Endocrinol; 2010 Feb; 38(2):95-102. PubMed ID: 19781890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
    Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients With Long-QT Syndrome Caused by Impaired
    Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
    Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired Secretion of Glucagon-Like Peptide 1 in Patients with Colorectal Adenoma after an Oral Glucose Load.
    Sasaki Y; Abe Y; Takeda H; Nishise S; Yaoita T; Yagi M; Sakuta K; Mizumoto N; Shoji M; Onozato Y; Kawata S; Ueno Y
    Digestion; 2018; 97(4):324-332. PubMed ID: 29539609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis.
    Calanna S; Piro S; Di Pino A; Maria Zagami R; Urbano F; Purrello F; Maria Rabuazzo A
    Obesity (Silver Spring); 2013 Feb; 21(2):320-5. PubMed ID: 23404781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum adipokine concentrations in dogs with naturally occurring pituitary-dependent hyperadrenocorticism.
    Cho KD; Paek J; Kang JH; Chang D; Na KJ; Yang MP
    J Vet Intern Med; 2014; 28(2):429-36. PubMed ID: 24372863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism.
    Hanson JM; Teske E; Voorhout G; Galac S; Kooistra HS; Meij BP
    J Neurosurg; 2007 Oct; 107(4):830-40. PubMed ID: 17937231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of the addition of pasireotide to traditional adrenal-directed treatment for dogs with pituitary-dependent hyperadrenocorticism secondary to macroadenoma: 9 cases (2013-2015).
    Lottati M; Bruyette DS
    J Am Vet Med Assoc; 2018 Jun; 252(11):1403-1408. PubMed ID: 29772978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog.
    Johnson KM; Farmer T; Schurr K; Patrick Donahue E; Farmer B; Neal D; Cherrington AD
    Endocrine; 2011 Jun; 39(3):229-34. PubMed ID: 21547512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance.
    Jørgensen NB; Jacobsen SH; Dirksen C; Bojsen-Møller KN; Naver L; Hvolris L; Clausen TR; Wulff BS; Worm D; Lindqvist Hansen D; Madsbad S; Holst JJ
    Am J Physiol Endocrinol Metab; 2012 Jul; 303(1):E122-31. PubMed ID: 22535748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
    Green BD; Irwin N; Gault VA; Bailey CJ; O'Harte FP; Flatt PR
    J Endocrinol; 2005 May; 185(2):307-17. PubMed ID: 15845923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.